“A smart man makes a mistake, learns from it, and never makes that mistake again. But a wise man finds a smart man and learns from him how to avoid the mistake altogether.” Roy H. Williams

 

Truffaldino has concluded a range of projects for biotechnology and medtech and diagnostic clients covering business development, corporate development and financing. Some examples are listed below:

Case Study 1: Vaccine licensing:

Truffaldino was tasked with identifying a development and commercial partner for a mid-stage vaccine clinical development project for a European client. After short data and market reviews, the project was re-positioned and then a limited number of potential licensees approached where there was a clear strategic fit with the partners’ product portfolio. The client entered into a financially significant term sheet with a major pharmaceutical partner within six months of Truffaldino initiating the project

Case Study 2: Oncology development pipeline repositioning:

A small oncology development stage company engaged Truffaldino to undertake a strategic review of its oncology development pipeline and establish a new direction for the business. This resulted in a new business plan which Truffaldino assisted in implementing resulting in the establishment of a new management team, a broader IP estate and renewed interest from investors resulting in a £10m capital raise.

Case Study 3: IPO support:

Truffaldino was contracted to write and verify a prospectus for a speciality pharmaceutical company planning an IPO on a major financial market. The prospectus and full verification notes were completed in under a month to the satisfaction of the client and financial and legal advisers.

Case Study 4: Merger and Acquisition Pipeline:

A medtech company commissioned Truffaldino to develop a qualified pipeline of acquisition candidates. Within 3 weeks the client received a qualified target list which resulted in immediate engagement with 3 target companies. This project was completed in a fraction of the time and at a fraction of the cost quoted by sector specialist investment banks.